Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised

Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overwei

Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.38) per share which beat the analys

Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset ra

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 202

HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy an

CHARLESTOWN, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "C

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Co

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and main

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lower

Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.52) per share which missed the anal

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part o

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part o

CHARLESTOWN, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Co

- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5

- Orphan drug designation from the European Commission underscores Solid's commitment to advance

- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT

CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “C

Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) shot up 5.5% on Thursday after Tru

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and rai

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy a

Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) has received an average recommendation of "M

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) wit

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.53) per share which missed the anal

- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annu

Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% i

Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcri

Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediat

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and raise

Solid Biosciences Inc. (NASDAQ: SLDB) shares are tumbling on Wednesday following a recent update reg

Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious des

- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date -- Robust micro

- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust micr

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and main

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording g

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines

- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences co